Access the full text.
Sign up today, get DeepDyve free for 14 days.
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
P390Evaluation of biosimilar insulin use: Perception and experience (INSPIRE)R DONNELLY, M Burke, L Haire, S Baxter and W MundayDiabetes Team, South Eastern Health & Social Care Trust, Dundonald, UKBackground: Abasaglar, the first UK licensed biosimilar insulin glargine, has been shown not to have any clinically significant differences from Lantus in terms of quality, safety and efficacy. Future diabetes management will see an expansion in the availability of biosimilar insulin and has the potential to offer the National Health Service considerable cost savings. Patient and clinical staff perspectives may be an important determinant in the success or failure of this exciting development in diabetes care.Aims: The aim of this evaluation was to explore perceptions of Abasaglar prescribing within the South Eastern Health and Social Care Trust diabetes team. The evaluation also sought to explore the experiences of patients prescribed Abasaglar compared to those prescribed Lantus.Methods: Clinical staff were made aware of the rationale for the service evaluation. Education sessions were provided and staff were invited to consider prescribing Abasaglar according to current National Institute for Health and Care Excellence (NICE) guidelines. Questionnaires were circulated at baseline and nine months. Perspectives assessed; staff insight, viewpoint, attitudes and barriers to prescribing biosimilar
Diabetic Medicine – Wiley
Published: Jan 1, 2018
Access the full text.
Sign up today, get DeepDyve free for 14 days.